African Global Pharma Corp. Receives Approval to Produce Anti-diabetic Tablet Glibenclamide
PR Log - Nov 07, 2012 - Emerging World Pharma Inc. Strategic Partner African Global Pharma Corp. Receives Approval to Produce Anti-diabetic Tablet Glibenclamide
Sunyani Ghana- November 7, 2012--Emerging World Pharma Inc. (OTC:EWPI)-Emerging World Pharma Inc. strategic partner African Global Pharma Corp.(AGP) has received full approval from the Food & Drugs Board of Ghana to produce and distribute an anti-diabetic pharmaceutical called Glibenclamide. The Food and Drugs Board of Ghana is a Ghanaian government agency responsible for the inspection, certification and proper distribution of foods and food products and drugs in Ghana.
The hypoglycemic agent is prescribed as an adjunct to diet and used to lower blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II). Glibenclamide is used for patients whose hypoglycemia cannot be controlled adequately by diet, physical exercise and weight reduction.
African Global Pharma Gh has been ramping up their Ghana manufacturing facility to provide for ongoing production and distribution of the product. Glibenclamide will be made available in 5 tablet packs that will contain 5mg of glibenclamide per tablet.
About African Global Pharma, Ghana African Global Pharma (Ghana) Limited is an affiliated company of African Global Pharma Corp. of Canada with business partnership with the Catholic Diocese of Sunyani to distribute all our manufactured drugs to the Catholic Mission Hospitals. African Global Pharma’s production facility in Sunyani, Ghana was fully rehabilitated and built by African Global Pharma Corp, Canada. The plant and its operations are headquartered in Sunyani at the Diocesan Bldg.
Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.
The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.